Stockreport

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interferin [Read more]